我国麻醉药品和精神药品行政监管法规完善建议

中国药物警戒 ›› 2018, Vol. 15 ›› Issue (1): 28-31.

我国麻醉药品和精神药品行政监管法规完善建议

樊莹莹¹, 齐莹莹², 穆星佳¹, 王晨慧¹, 姜庆丹^1,*, 乔明娟³

1 辽宁中医药大学研究生学院,辽宁沈阳10847;
2 济南市历城区人民法院,山东济南 250014;
3 山东华宇工学院,山东德州 253034;

收稿日期:2018-02-12 修回日期:2018-02-12 出版日期:2018-01-20 发布日期:2018-02-12
通讯作者: *姜庆丹,女,博士·硕导,药事管理。E-mail：jiangqingdan9869@163.com
作者简介:樊莹莹,女,在读硕士,药事管理。

Suggestions on Improvement of Administrative Regulations on Narcotic Drugs and Psychotropic Drugs in China

FAN Ying-ying¹, QI Ying-ying², MU Xing-jia¹, WANG Chen-hui¹, JIANG Qing-dan^1,*, QIAO Ming-juan³

1 College of Postgraduate, Liaoning University of Traditional Chinese Medicine, Liaoning Shenyang 110847, China;
2 Licheng District People's Court, Jinan, Shandong Jinan 250014, China;
3 Shandong Huayu University of Technology, Shandong Dezhou 253034, China;

Received:2018-02-12 Revised:2018-02-12 Online:2018-01-20 Published:2018-02-12

摘要/Abstract

摘要： 目的分析自《中华人民共和国药品管理法》颁布实施以来,我国麻醉药品和精神药品（简称“麻精药品”）行政监管法规体系的现状,探索实践中麻精药品法律法规体系凸显的不足和缺陷,并提出完善建议。方法检索分析大量文献,整理麻精药品的行政监管立法沿革,探索麻精药品监管法规体系的不足和缺陷。结果麻精药品行政监管法规存在的不足与缺陷,不能有效满足多元复杂的行政执法活动。结论建议及时分析行政法规体系不足与缺陷,完善行政法规,提高麻精药品的行政监管水平。

关键词: 麻醉药品, 精神药品, 法规, 完善建议

Abstract: Objective To analyze the status of the administrative supervision and regulation system of narcotic drugs and psychotropic drugs (hereinafter referred to as "the two drugs") in our country since the promulgation and implementation of the Drug Administration Law of the People's Republic of China, so as to explore the shortcomings and deficiencies in the laws and regulations in practice and propose suggestions. Methods A large number of documents were searched and analyzed, legislative evolution of administrative supervision were collected and arranged, The shortcomings and deficiencies of the regulation system were explored. Results The shortcomings and deficiencies in the laws and regulations of administrative supervision could not effectively meet the needs of multiple and complex administrative law enforcement activities. Conclusion It is suggested to analyze the shortcomings and deficiencies of administrative laws and regulations in time, perfect the administrative regulations and improve the administrative supervisioan.

Key words: narcotic drugs, psychotropic drugs, regulations, suggestions for perfection

中图分类号:

R951

樊莹莹, 齐莹莹, 穆星佳, 王晨慧, 姜庆丹, 乔明娟. 我国麻醉药品和精神药品行政监管法规完善建议[J]. 中国药物警戒, 2018, 15(1): 28-31.

FAN Ying-ying, QI Ying-ying, MU Xing-jia, WANG Chen-hui, JIANG Qing-dan, QIAO Ming-juan. Suggestions on Improvement of Administrative Regulations on Narcotic Drugs and Psychotropic Drugs in China[J]. Chinese Journal of Pharmacovigilance, 2018, 15(1): 28-31.

参考文献

[1] 国务院.麻醉药品和精神药品管理条例[S].2005-08-03.
[2] 李润华. 药品安全的刑法保护[J].中国卫生法制,2012,20(4):5-6.
[3] 满春霞,邹武捷,杨淑萍,等. 麻醉药品和精神药品管制研究Ⅳ—我国麻醉药品和精神药品的管制历程与现状[J].中国药房,2017,28(1):18-22.
[4] 陈鸣. 中国麻醉药品管理历史沿革及医疗机构麻醉药品管理[J].中国医院药学杂志,2015,35(5):375-379.
[5] 王晓磊. 麻醉药品和精神药品监管主体法律问题研究[D].天津:天津师范大学,2014.
[6] 谢顶仁,杨华萍,朱腊荣,等. 医疗卫生机构在执行《麻醉药品和精神药品管理条例》过程中存在的问题及对策[J].中国药房,2013,24(25):2397-2400.
[7] 邹武捷,满春霞, 杨淑萍,等. 麻醉药品和精神药品管制研究Ⅱ—美国管制物质的管制历程与现状[J].中国药房,2017,28(1):10-14.
[8] UNODC.Single convention on narcotic drug 1961[EB/OL].(2013)[2017-05-30].http://www.unodc.org/documents/commissions/CND/Int_Drug_Control_Conventions/1961_Schedules/ST-CND-1-Add1_C.pdf.
[9] Wikipedia. Misuse of Drugs Act 1971[EB/OL].[2016-05-10].http://en.wikipedia.org/wiki/Misuse _of_ Drugs_Act_1971.
[10] 刘勇,吴晓明,顾建琴.我国麻醉药品监管发展问题及域外启示[J].中国新药杂志,2015,24(22):2540-2554.
[11] Advisory Council on the Misuse of Drugs. About us[EB/OL].[2016-05-20].https//www.gov.uk/government/organisations/advisory-council-on-the-misuse-of-drugs/about.
[12] Advisory Councilonthe Misuseof Drugs. Our governance [EB/OL].[2016-05-20]. https//www.gov.uk/government/organisations/advisory-council-on-the-misuse-of-drugs/about/our-gove-rnance.
[13] INCB.The international narcotics control board[EB/OL].[2016-03-22]. http://www.incb.org/incb/en/index.html.
[14] 韦宁,盘红梅,廖艺. 基于PDCA 循环的病区麻醉药品、第一类精神药品管理研[J].中国药物警戒,2015,12(8):500-502.
[15] 闫泉,邵蓉.美国麻精药品监管制度评价[J].现代商贸工业,2014,26(19):68-69.
[16] 马军丽,逄立艳,周立新,等.氨酚羟考酮依赖性及滥用风险分析[J]. 中国药物警戒, 2012,9(8):476–478.